-
Prof. Jian Zhang: Precision and Innovation Driving the New “Red Book” in Breast Cancer Care in China
Editor’s Note The 17th Shanghai Breast Cancer Professional Symposium, held in conjunction with the Annual Meeting of the Breast Cancer Committee of the Shanghai Anti-Cancer Association and the 2026 Breast…
-
Professor Zefei Jiang: The Northern Breast Cancer Salon Returns
A Comprehensive Review of Annual Advances and Guideline Updates, and a Look Ahead at New Trends in Clinical Practice 丨Northern Breast Cancer Salon Editor’s Note As the year turns, another…
-
2026 CASH丨Professor Xiaofan Zhu: New Directions in Pediatric Hematologic Malignancies Through the Lens of ASH Frontiers
Editor’s Note At the beginning of the new year, distinguished experts gathered in Tianjin. From January 9 to 11, 2026, the 6th China Congress on the Advancement of Hematology (CASH)…
-
2026 CASH | Professor Jianqing Mi: Advances and Future Directions of CAR-T Cell Therapy in Multiple Myeloma
Editor’s Note At the dawn of the new year, leading experts convened in Tianjin. From January 9 to 11, 2026, the 6th China Congress on the Advancement of Hematology (CASH)…
-
2026 CASH | Professor Lugui Qiu: Annual Review of the 2025 Multiple Myeloma Guidelines
Editor’s Note At the beginning of the new year, leading experts gathered in Tianjin. From January 9 to 11, 2026, the 6th China Congress on the Advancement of Hematology (CASH)…
-
CASH 2026 | Prof. Wang Tianyou: Forty Years of Change in China’s Pediatric Disease Spectrum and Strategic Responses
With the dawn of the new year, Tianjin once again became a hub for academic exchange. From January 9 to 11, 2026, the 6th China Annual Conference on the Development of Hematology (CASH) was grandly held in Tianjin. Bringing together leading experts in hematology from China and abroad, the conference focused on disciplinary frontiers and…
-
Lymphoma In-Depth · ASH Special | Professor Qingqing Cai: New Advances in First-Line Treatment of Marginal Zone Lymphoma
The 2025 Annual Meeting of the American Society of Hematology (ASH 2025) recently concluded successfully in Orlando, USA. As the “year-end flagship event” in hematology, ASH 2025 presented a series of landmark advances in the field of lymphoma, offering new directions for optimizing clinical practice.
-
ASH Global Perspectives | Prof. Wojciech Jurczak: First Results of BRUIN CLL-313 Suggest Non-Covalent BTK Inhibitors May Reshape First-Line CLL/SLL Treatment
Chronic lymphocytic leukemia (CLL) / small lymphocytic lymphoma (SLL) is a clonal proliferative disorder of mature B cells that predominantly affects older adults and is characterized by a distinctive immunophenotype. At the Late-Breaking Abstract (LBA) session of the 2025 American Society of Hematology (ASH) Annual Meeting, Professor Wojciech Jurczak from the Maria Skłodowska-Curie National Research…
Connecting Medical Expertise through Media